Abstract
BCR-ABL positive (+) acute lymphoblastic leukemia (ALL) accounts for ~30% of cases of ALL. We recently demonstrated that 2-deoxy-d-glucose (2-DG), a dual energy (glycolysis inhibition) and ER-stress (N-linked-glycosylation inhibition) inducer, leads to cell death in ALL via ER-stress/UPR-mediated apoptosis. Among ALL subtypes, BCR-ABL+ ALL cells exhibited the highest sensitivity to 2-DG suggesting BCR-ABL expression may be linked to this increased vulnerability. To confirm the role of BCR-ABL, we constructed a NALM6/BCR-ABL stable cell line and found significant increase in 2-DG-induced apoptosis compared to control. We found that Mcl-1 was downregulated by agents inducing ER-stress and Mcl-1 levels correlated with ALL sensitivity. In addition, we showed that Mcl-1 expression is positively regulated by the MEK/ERK pathway, dependent on BCR-ABL, and further downregulated by combining ER-stressors with TKIs. We determined that energy/ER stressors led to translational repression of Mcl-1 via the AMPK/mTOR and UPR/PERK/eIF2α pathways. Taken together, our data indicate that BCR-ABL+ ALL exhibits heightened sensitivity to induction of energy and ER-stress through inhibition of the MEK/ERK pathway, and translational repression of Mcl-1 expression via AMPK/mTOR and UPR/PERK/eIF2α pathways. This study supports further consideration of strategies combining energy/ER-stress inducers with BCR-ABL TKIs for future clinical translation in BCR-ABL+ ALL patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1246-1254 |
Number of pages | 9 |
Journal | Leukemia Research |
Volume | 39 |
Issue number | 11 |
DOIs | |
State | Published - May 13 2015 |
Keywords
- 2-deoxy-d-glucose
- AMPK
- Acute lymphoblastic leukemia
- Apoptosis
- BCR-ABL+
- Combination targeted therapy
- Dasatinib
- ER stress
- ERK
- Energy stress
- Imatinib
- Leukemia
- Mcl-1
- Tyrosine kinase inhibitors
- UPR
- eIF2α
- shRNA
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research